netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Aflibercept (Zaltrap®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vials: 100mg/4ml, 40mg/1ml

 
Link  NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA 346: Aflibercept for treating diabetic macular oedema
Link  NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
   
Atezolizumab
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund
NHS England

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

Also available through patient access scheme for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy 
Link  NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA 638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA 639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA 666:Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
   
Avelumab Black Triangle (Bavencio ®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

20mg/ml concentrate for infusion.

 
Link  NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma
   
Axicabtagene ciloleucel
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
 
Link  NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies
   
Axitinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Film coated tablets: 1mg, 3mg, 5mg and 7mg

 
Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bosutinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Film coated tablets: 100mg, 500mg

 
Link  NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
   
Carfilzomib (Kyrolis®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

Vial: powder for infusion 10 mg, 30 mg and 60 mg

 
Link  NICE TA 657: Carfilzomib for previously treated multiple myeloma
   
Ceritinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsule: 150mg

 
Link  NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules: 50mg and 75mg

  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
  • Link  NICE TA 321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
       
    DaratumumabBlack Triangle (Darzalex ®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    20mg/ml concentrate for infusion

     
    Link  NICE TA 510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
    Link  NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
       
    Encorafenib (Braftovi®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Capsules: 50 mg and 75 mg

     
    Link  NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
    Link  NICE TA 668:Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
       
    Entrectinib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Capsules: 100mg and 200mg

     
    Link  NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
    Link  NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours
       
    Cytotoxic Drug Eribulin (Halaven®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 0.88mg/2ml
    Vial: 1.32mg/3ml

     
    Link  NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
       
    Gemtuzumab ozogamicin (Mylotarg®)
    View adult BNF View SPC online
    Formulary
    Red
  • Approved for untreated acute myeloid leukaemia in line with NICE 
  • Link  NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
       
    Gilteritinib (as fumarate)
    View adult BNF View SPC online
    Formulary
    High Cost Medicine
    NHS England

    Tablets: 40mg

     
    Link  NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
       
    Ibrutinib (Imbruvica®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 140mg

     
    Link  NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
    Link  NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
       
    Idelalisib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Film coated tablets: 100mg, 150mg

     
    Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
       
    Inotuzumab ozogamicin (Besponsa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE 
  • Link  NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
       
    Ixazomib (Ninlaro®)
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 4mg

     
    Link  NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
       
    Cytotoxic Drug Lenvatinib (Lenvima®)
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 4mg and 10mg

     
    Link  NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
    Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
    Link  NICE TA 551: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma
       
    Cytotoxic Drug MidostaurinBlack Triangle (Rydapt ®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England
    25mg capsules 
    Link  NICE TA 522 Midostaurin for untreated acute myeloid leukaemia
       
    Cytotoxic Drug Niraparib (Zejula®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    Niraparib tosylate monohydrate 100mg capsules 
    Link  NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer
       
    Olaparib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Capsules: 50mg

    - Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed

    - approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in line with NICE

     
    Link  NICE TA 598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
    Link  NICE TA 620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
       
    Olaratumab
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for solution for infusion: 10 mg/mL

     
       
    Osimertinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablet: 40mg and 80mg

     
    Link  NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
    Link  NICE TA 654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Pablociclib (Ibrance®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Recommended for use according to NICE criteria

     
    Link  NICE TA 619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Panobinostat (Farydak®)
    View adult BNF View SPC online
    Formulary
    Red

    Hard capsules: 10mg, 15mg, 20mg

     
    Link  NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
       
    Pembrolizumab (Keytruda®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Concentrate for infusion: 100 mg/4 mL

    See below for NICE approved indications

     
    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
    Link  NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
    Link  NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA 522 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer where cisplatin is unsuitable
    Link  NICE TA 531: Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer
    Link  NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
    Link  NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
    Link  NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
    Link  NICE TA 661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
       
    Polatuzumab vedotin
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Vial: 30mg and 150mg, powder for concentrate for solution for infusion.

     
    Link  NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
       
    Ponatinib (Iclusig®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 15mg, 45mg

     
    Link  NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Radium-223 dichloride
    View adult BNF View SPC online
    Formulary
    Red
     
    Link  NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
       
    Rucaparib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Film coated tablets: 200mg, 250mg, 300mg

     
    Link  NICE TA 611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
       
    Ruxolitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 5mg, 15mg, 20mg

     
    Link  NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
       
    Talimogene laherparepvec (Imlygic®)
    View adult BNF View SPC online
    Formulary
    Red

    Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


    -approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

     
    Link  NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
       
    Tisagenlecleucel (Kymriah®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
  • Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE

  • NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. 
  • Link  NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
    Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
       
    TivozanibBlack Triangle (Fotivda® )
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 890 mg and 1340 mg

     

     
    Link  NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
       
    Trametinib (Mekinist®)
    View adult BNF View SPC online
    Formulary
    Red

    Film coated tablets: 500microgram, 2mg

     
    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
       
    08.01.05  Expand sub section  Amsacrine
    Cytotoxic Drug Amsacrine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 75mg in 15ml

     
       
    08.01.05  Expand sub section  Arsenic trioxide
    Cytotoxic Drug Arsenic Trioxide
    View adult BNF View SPC online
    Formulary
    Red

    Ampoule: 10mg in 10ml
    -NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)

    NICE TA for acute promyelocytic leukaemia 
    Link  NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia
       
    08.01.05  Expand sub section  Bevacizumab
    Bevacizumab (Avastin®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 100mg/4ml
    Syringe: 5mg/0.2ml
    Solution for infusion: 25mg/1ml


    *Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable

     
    Link  NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
    Link  NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
    Link  NICE TA 212: Colorectal cancer (metastatic) - bevacizumab
    Link  NICE TA 214: Breast Cancer with taxane
    Link  NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA 263: Breast cancer with capecitabine
    Link  NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
    Link  NICE TA 285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
       
    08.01.05  Expand sub section  Bexarotene to top
    08.01.05  Expand sub section  Bortezomib
    Cytotoxic Drug Bortezomib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Injection: 3.5mg

     
    Link  NICE TA 129: Multiple myeloma - bortezomib
    Link  NICE TA 228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
    Link  NICE TA 311: Multiple myeloma - bortezomib (induction therapy
    Link  NICE TA 370: Bortezomib for previously untreated mantle cell lymphoma
       
    08.01.05  Expand sub section  Brentuximab vedotin
    Brentuximab vedotin (Adcetris®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    Vial: 50mg

     
    Link  NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
    Link  NICE TA 577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
    Link  NICE TA 641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
       
    08.01.05  Expand sub section  Cetuximab
    Cetuximab
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vials for IV infusion: 100mg in 20ml & 500mg in 100ml

     
    Link  NICE TA 118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
    Link  NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA 323 Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
    Link  NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
    Link  NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
    Link  NICE TA 473: Head and neck cancer (squamous cell carcinoma) - cetuximab
       
    08.01.05  Expand sub section  Crisantaspase
    08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
    Cytotoxic Drug Dacarbazine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 500mg

     
       
    Cytotoxic Drug Streptozocin
    View adult BNF View SPC online
    Formulary
    Red

    unlicensedunlicensed Injection: 1g (only available on a named patient basis)

     
       
    Cytotoxic Drug Temozolomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 5mg, 20mg, 100mg, 250mg

     
    Link  NICE TA 23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
    Link  NICE TA 121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
       
    08.01.05  Expand sub section  Erlotinib
    Cytotoxic Drug Erlotinib (Tarceva® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 25mg, 100mg & 150mg

     
    Link  NICE TA 227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
    Link  NICE TA 258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
    Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    08.01.05  Expand sub section  Hydroxycarbamide
    Hydroxycarbamide
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 500mg
    unlicensedunlicensed Suspension: 500mg in 5ml

     
       
    08.01.05  Expand sub section  Imatinab
    08.01.05  Expand sub section  Ipilimumab
    Ipilimumab
    View adult BNF View SPC online
    Formulary
    Red

    Vial for preparing IV infusion: 50mg

     
    Link  NICE TA 268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
    Link  NICE TA 319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
       
    08.01.05  Expand sub section  Mitotane to top
    Mitotane
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 500mg

     
       
    08.01.05  Expand sub section  Panitumumab
    08.01.05  Expand sub section  Pentostatin
    08.01.05  Expand sub section  Platinum compounds
    Cytotoxic Drug Carboplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 50mg in 5ml, 450mg in 45ml

     
       
    Cytotoxic Drug Cisplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 50mg

     
       
    Cytotoxic Drug Oxaliplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 50mg, 100mg

     
    Link  NICE TA 100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
       
    08.01.05  Expand sub section  Porfimer sodium and temoporfin
    08.01.05  Expand sub section  Procarbazine to top
    Cytotoxic Drug Procarbazine
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 50mg

     
       
    08.01.05  Expand sub section  Protein kinase inhibitors
    Afatinib
    View adult BNF View SPC online
    Formulary
    Red

    Film coated tablets: 20mg, 30mg, 40mg, 50mg

     
    Link  NICE TA 310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
       
    Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England
    150mg capsules 
    Link  NICE TA 536: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
       
    Cytotoxic Drug Brigatinib (Alunbrig®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE 
  • Link  NICE TA 570: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
       
    Cytotoxic Drug Cabozantinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy 
  • Link  NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 200mg, 250mg

     
    Link  NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dacomitinib (Vizimpro®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England

    Dacomitinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides it according to the commercial arrangement.

     
    Link  NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Cytotoxic Drug Dasatinib
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 20mg, 50mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Everolimus (Votubia®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 2.5mg, 5mg, 10mg


    -Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
    -a
    pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


    Tablets: 5mg and 10mg


    - Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    - Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
    - Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    -Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


     

     
    Link  NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
    Link  NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Gefitinib (Iressa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 250mg

     
    Link  NICE TA 192: Lung cancer (non-small-cell, first line) - gefitinib
    Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    Cytotoxic Drug Imatinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 100mg & 400mg

     
    Link  NICE TA 70: Leukaemia (chronic myeloid) - imatinib
    Link  NICE TA 86: Gastro-intestinal stromal tumours (GIST) - imatinib
    Link  NICE TA 209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
    Link  NICE TA 326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Larotrectinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    Cancer Drugs Fund

    Oral solution: 20mg/mL

    Recommended for use according to NICE criteria (TA630)

     
    Link  NICE TA 630: Larotrectinib for treating NTRK fusion-positive solid tumours
       
    Lorlatinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    NHS England

    Tablets: 25mg, 100mg

     

    Recommended for use according to NICE criteria (TA628)

     
    Link  NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
       
    Nilotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 150mg, 200mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Nintedanib (Vargatef®)
    View adult BNF View SPC online
    Formulary
    Red

    Soft capsules: 100mg, 150mg

     
    Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
    Link  NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
       
    Pazopanib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 200mg, 400mg

     
    Link  NICE TA 215: Renal cell carcinoma (first line metastatic) - pazopanib
       
    Regorafenib (Stivarga® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 40mg

     
    Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
    Link  NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
       
    Sorafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 200mg

     
    Link  NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sunitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 50mg 100mg, 400mg

     
    Link  NICE TA 169: Renal cell carcinoma - sunitinib
    Link  NICE TA 178: Renal cell carcinoma
    Link  NICE TA 179: Gastrointestinal stromal tumours - sunitinib
       
    Trifluridine and tipiracil
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

     
    Link  NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
       
    Vemurafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 240mg

     
    Link  NICE TA 269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
    Link  NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Venetoclax (Venclyxto®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablets: 10 mg, 50 mg & 100 mg

     
    Link  NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
    Link  NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
       
    08.01.05  Expand sub section  Taxanes
    Cytotoxic Drug Abraxane® (Paclitaxel)
    View adult BNF View SPC online
    Formulary
    Red

    Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.

     
    Link  NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
       
    Cytotoxic Drug Cabazitaxel
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Concentrate for IV infusion: 40mg/1ml

     
    Link  NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
       
    Cytotoxic Drug Docetaxel
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 20mg, 80mg

     
    Link  NICE TA 101: Prostate cancer (hormone-refractory) - docetaxel
       
    Cytotoxic Drug Paclitaxel
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml

     
    Link  NICE NG 101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA 55: Ovarian cancer - paclitaxel (review)
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    Cytotoxic Drug Irinotecan
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 40mg in 2ml & 100mg in 5ml

     
       
    Cytotoxic Drug Topotecan
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 0.25mg, 1mg capsules
    Vials: 1mg, 4mg

     
    Link  NICE TA 183: Cervical cancer (recurrent) - topotecan
    Link  NICE TA 184: Lung cancer (small-cell) - topotecan
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Expand sub section  Trabectedin
    Cytotoxic Drug Trabectedin (Yondelis®)
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 250microgram

     
    Link  NICE TA 185: Soft tissue sarcoma - trabectedin
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Expand sub section  Trastuzumab to top
    Cytotoxic Drug Pertuzumab (Perjeta®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 420mg

     
    Link  NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
    Link  NICE TA 569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
       
    Cytotoxic Drug Trastuzumab (Herceptin®)
    View adult BNF View SPC online
    Formulary
    Red

    Vial for preparing IV infusion: 150mg
    Injection: 600mg s/c injection

     
    Link  NICE TA 101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA 208: Gastric cancer (HER2-positive metastatic) - trastuzumab
    Link  NICE TA 257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
    Link  NICE TA 34: Breast cancer - trastuzumab
       
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA 235: Osteosarcoma - mifamurtide
    Link  NICE TA 632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
       
    08.01.05  Expand sub section  Tretinoin
    Tretinoin
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 10mg

     
       
    08.01.05  Expand sub section  Vismodegib
     ....
     Non Formulary Items
    Bexarotene  (Targretin®)

    View adult BNF View SPC online
    Non Formulary
     
    Crisantaspase  (Erwinase®)

    View adult BNF View SPC online
    Non Formulary
     
    Ixazomib  (Ninlaro®)

    View adult BNF View SPC online
    Non Formulary
     
    Necitumumab

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Cytotoxic Drug  Panitumumab  (Vectibix®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Cytotoxic Drug  Pentostatin  (Nipent®)

    View adult BNF View SPC online
    Non Formulary
     
    Porfimer Sodium  (Photofrin ®)

    View adult BNF View SPC online
    Non Formulary
     
    Sonidegib  (Odomzo®)

    View adult BNF View SPC online
    Non Formulary
     
    Temoporfin  (Foscan®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Vandetanib  (Caprelsa®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Cytotoxic Drug  Vismodegib  (Erivedge®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Vosaroxin  (Qinprezo)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary